Trials / No Longer Available
No Longer AvailableNCT01260779
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
Open Label Expanded Access for Investigational Use of PV-10 in Patients Who Are Not Eligible for an Existing PV-10 Clinical Trial, for Whom There is no Alternative Therapy, and Whom May Benefit From PV-10 Administration
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Provectus Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable or satisfactory approved alternative therapy and whom, in the opinion of the investigator, may benefit from PV-10 administration.
Conditions
- Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory
- Approved Alternative Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PV-10 (10% rose bengal disodium) | Intralesional injection for chemoablation of cutaneous or subcutaneous lesions |
Timeline
- First posted
- 2010-12-15
- Last updated
- 2016-07-11
Locations
6 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT01260779. Inclusion in this directory is not an endorsement.